Understanding the pathogenesis of type-I diabetes (T1D) is hindered in humans by the long autoimmune process occurring before clinical onset and by the difficulty to study the pancreas directly. Alternatively, exploring body fluids and particularly peripheral blood can provide some insights. Indeed, circulating cells can function as 'sentinels', with subtle changes in gene expression occurring in association with disease. Therefore, we investigated the gene expression profiles of circulating blood cells using Affymetrix microarrays. Whole-blood samples from 20 first-degree relatives of T1D children with autoimmune diabetes-related antibodies, 19 children immediately after the onset of clinical T1D and 20 age-and sex-matched healthy controls were collected in PAXgene tubes. A global gene expression analysis with MDS approach allowed the discrimination of pre-diabetic subjects, diabetic patients and healthy controls. Univariate statistical analysis highlighted 107 distinct genes differently expressed between these three groups. Two major gene expression profiles were characterized, including type-I IFN-regulated genes and genes associated with biosynthesis and oxidative phosphorylation. Our results showed the presence of early functional modifications associated with T1D, which could help to understand the disease and suggest possible avenues for therapeutic interventions.
Introduction
Type-I diabetes (T1D) is an autoimmune disease that results from the destruction of insulin-producing b-cells in the pancreas. Antibodies against b-cell components can be detected in the sera of pre-diabetic subjects (PT1D), indicating an ongoing autoimmune process during a long asymptomatic preclinical period. 1 These antibodies serve as markers of a b-cell-targeted immune reaction, although b-cell damage remains generally regarded as a process that is mainly T-cell-mediated. 2 Most of our understanding of the mechanisms leading to selective b-cell loss is derived from animal models such as the NOD mouse. 3 However, this does not necessarily reflect the human situation and several questions remain to be answered. Little is known about the genetic and/or environmental factors that modulate the rate of b-cell loss in predisposed subjects. In addition, recent observations of persistent b-cells in the pancreas of patients with longstanding diabetes 4 are puzzling and suggest that regeneration and destruction of b-cells is a lifelong process. Although most clinical cases of T1D appear de novo, first-degree relatives of T1D patients have a relative risk of 7-89% to develop the disease depending on the degree of genetic concordance and antibody status. 5 Prediction of T1D is commonly based on the number and titer of diabetes-associated autoantibodies, including anti-insulin (IAA), anti-tyrosine phosphatase (IA-2) or anti-glutamic acid decarboxylase-65 (GAD65) antibodies. 6 However, some relatives with multiple autoantibodies do not develop diabetes and the time to develop clinical diabetes in antibody-positive relatives cannot be calculated accurately, indicating that additional markers that directly reflect the balance between pathogenic and protective mechanisms are required. 5 Genome-wide gene expression profiling using microarrays is a powerful technology. It was recently applied to the prediction of the outcome of T1D 7 and the identification of genes and pathways dysregulated 8 from the analysis of peripheral blood mononuclear cells of T1D patients. However, this approach has never been employed directly on peripheral whole-blood cells. In this study, we have explored the hypothesis that gene expression profiling of peripheral whole-blood cells may provide new insights into the pathophysiology of T1D.
Results
Transcriptomic analysis of whole blood Multidimensional scaling. Taking each gene expression profile as a whole (n ¼ 54 675 probe sets), we first used a multidimensional scaling (MDS) approach to display the position of each T1D patient (n ¼ 19), PT1D (n ¼ 20) and control (n ¼ 20) sample in a three-dimensional Euclidean space. In the MDS plot in Figure 1 , the distance between the samples reflect their approximate degree of transcriptional similarity. PT1D, T1D patients and controls appear distributed into three separate groups, with few exceptions, suggesting different global gene expression patterns.
Identification of differentially expressed genes. To underline the most discriminant genes, the samples were randomly divided into two experimental sets (Set-1: n ¼ 10 PT1D, 10 T1D patients, 10 control and Set-2: n ¼ 10 PT1D, 9 T1D patients, 10 controls). Analysis was performed by studying independently each set as well as the combination of both. For each analysis, invariant genes were removed as described under section 'Materials and methods'. Using bioinformatic and statistical analyses, 4288, 4694 and 10 713 probe sets were selected from Set-1, Set-2 and Set-1 þ 2, respectively. After Significant Analysis of Microarrays (SAM) statistical analyses between the three groups (PT1D, T1D and controls), we focused our analyses on the 144 probe sets (107 distinct UniGenes) commonly found in Set-1, Set-2 and Set-1 þ 2 comparisons ( Figure 2 ; see Supplementary Table S1 ). Statistical power was 0.65 for Set-1, 0.55 for Set-2 and 0.88 for Set-1 þ 2, confirming the relevance of the combinations used.
To obtain further details on the description of these 107 genes, pairwise comparisons (controls versus T1D patients, controls versus PT1D, T1D patients versus PT1D), associated with a false discovery rate (FDR) of 0.1, were performed on the Set-1 þ 2 combination. Overall, the majority of the genes identified among the 107 genes came from comparisons of the PT1D versus T1D patients and control versus T1D patients (See supplementary Table S1 ).
Cluster and ontology analysis of microarray data. Following the description of the 107 genes differentially expressed between the three groups, we analyzed the distribution of the expression patterns generated by the SAM test. K-means clustering allowed us to group the expression profiles into a limited number of clusters. The clearest representation of the expression profiles within the data set was obtained with a number of clusters k ¼ 2 (Figure 3a) , with a stability of 0.90 for cluster-1 and 0.94 for cluster-2. Cluster-1 corresponds to 39 genes mostly upregulated in PT1D and expressed at lower levels in controls and particular T1D patients. In contrast, cluster-2 contains 68 genes with expression decreased in PT1D and increased in T1D patients when compared with that in controls.
To draw a clear picture of the gene products in terms of their associated biological processes, we used the DAVID Functional Annotation Tool Suite and the EASE score P-value to further classify the selected genes. Ontological analysis of the 107 genes revealed 16 significantly enriched gene ontology (GO) biological Figure 1 A MDS of the three groups from the whole microarray data. On the basis of the normalized expression data, samples were represented in a three-dimensional Euclidean space. The color indicates the different groups of samples; blue represents the healthy controls, green the pre-diabetic subjects and red the diabetic patients. MDS, multidimensional scaling. A Venn diagram of differentially expressed genes obtained from statistical analyses of the three groups (SAM test, false discovery rate at 5%). The figure represents the number of probe sets differently expressed between the three groups (healthy controls, pre-diabetic subjects, diabetic patients) and shared among the three analyses (Set-1, Set-2 and Set-1 þ 2). From the intersection (Set-1-Set-2-Set-1 þ 2), 107 genes were selected (see Supplementary Table S1 ). SAM, Significant Analysis of Microarrays. (Figure 4) . Interestingly, we observed also that PT1D (IFN high ) have a mean expression equal to or higher than systemic lupus erythematosus (SLE) patients known to be the paradigm of IFN-induced disease.
To go further in the description of this biological signature, Ingenuity Pathway Analysis (IPA) was conducted on the 12 genes, which composed the IFN signature. IPA is capable not only of constructing associations of genes identified in our analysis ('focus' genes), but also of predicting the involvement of additional molecules not associated in the main list of genes. All genes were found in the IPA knowledge database, and are labeled 'focus genes'. On the basis of , similar to patients with SLE. Each point represents a single individual, with the average of microarray expression data from all 12 type-I IFN-response genes, which are present in cluster-1 ( Figure 3a , IFI27, OASL, SERPING1, ISG15, IFIT3, GBP1, IFIT2, IFIT1, OAS3, STAT1, RSAD2, IFI44). The gray box indicates the normal range within the 90th percentile confidence limits. Individuals outside the gray box are defined as the IFN high group. IFN, interferon; C, healthy controls; PT1D, pre-diabetic subjects; SLE, systemic lupus erythematosus patients; T1D, type-I diabetes patients.
Functional genomics in type-I diabetes F Reynier et al these focus genes IPA generated two biological networks identified around the IFNA, IFNB. The IFN signature was segregated into two separate networks. Network-a (score 28, focus genes 10; Figure 5a ) and Network-b, the less informative network (score 4, focus genes 2; Figure 5b ).These findings provide evidence that type-I IFNs rather than type-II IFNs are responsible for the increased expression of IFN-induced genes in PT1D.
Validation of microarray gene expression data. For a subset of patients (n ¼ 28), 10 selected genes were tested by quantitative reverse transcription-PCR (RT-PCR) ( Table 1) . A significant correlation was observed between the expression levels of these genes, as determined by DNA microarray hybridization and quantitative reverse transcription-PCR (RT-PCR) analysis (Table 2) .
Discussion
To investigate the mechanisms underlying the pathological process of T1D, we examined global gene expression profiles in pre-diabetic siblings and newly diagnosed T1D children. Thus, we highlighted new pathways affected at the early stages of the disease.
We hypothesized that blood transcriptome reflects physiological and pathological events occurring in inflamed islets, with blood cells acting as sentinels. Indeed, peripheral blood cells express a large proportion of genes encoded in the human genome, 9 which makes it possible to study clinically relevant changes in gene expression in a reproducible manner. Moreover, peripheral blood is an ideal surrogate tissue as it is readily obtainable and provides a large biosensor pool in the form of gene transcripts that respond to changes in the human body and its environment. Gene expression patterns might be influenced by quantitative variations of specific blood-cell subsets within subjects. However, we did not observe any significant change in blood-cell counts in T1D patients versus controls (data not shown). Consistently, a study describing gene expression in peripheral blood mononuclear cells showed that alterations in the composition or activation status of cell subsets did not account for the observed differences in gene expression between healthy and autoimmune populations such as T1D. 10 We used the PAXgene Blood RNA system that stabilizes the transcriptome and provides a standardized and reproducible method using small volumes of whole blood adapted to the study of young children. The PAXgene sampling system has been promulgated in a number of recent clinical studies looking at blood gene expression patterns based on microarray analyses or RT-PCR.
11,12 Moreover, we illustrated that mRNA quantification in PAXgene blood samples could help to describe the immune function and status of patients with septic syndromes. 13 Several additional elements can justify the use of whole blood with PAXgene as study material. This procedure reduces RNA degradation and prevents any post-sampling stimulation. 14, 15 In contrast, previous published studies showed that blood collection using EDTA tubes or leukocyte purification was accompanied by profound changes in mRNA expression. 15, 16 In this study, the conducted analyses have shown the interest provided by the combined approach (Set-1 þ 2) in comparison with that provided by individual sets (Set- Figure 5 The two gene networks (a, b) derived from the 12 genes, which composed the IFN signature, using the IPA software. Edges (gene relationship) are displayed with labels that describe the nature of the relationship between nodes (genes). The nodes are displayed using various shapes that represent the functional class of the gene product. Genes in red belong to the list of the 12 IFN-inducible genes. Genes in blue were integrated into the computationally generated networks on the basis of the evidence stored in the IPA knowledge memory indicating a relevance to this network. The pink arrows represent the direct and indirect interactions for genes of type-I IFN (IFN-a, IFN-b) . Network-a (score 28, focus genes 10) and Network-b (score 4, focus genes 2) show central connection represented by IFN-a, IFN-b. IFN, interferon; IPA, Ingenuity Pathway Analysis.
Functional genomics in type-I diabetes F Reynier et al 1 and Set-2). In fact, false-positive and false-negative rates are minimized when statistical power and sample size are increased. Moreover, interaction of the three analyses (Set-1-Set-2-Set-1 þ 2) also significantly reduced the risk of false positive by selecting genes that appeared independently of sampling. On the basis of this method, exploratory and confirmatory data analysis identified an autoimmune signature detectable years before the onset of disease using a transcriptome approach using whole blood. Many of the immune-response genes selected were grouped in cluster-1 (Figure 3a) composed mainly of genes upregulated in PT1D. The most statistically relevant gene family was represented by IFN-regulated genes. IFNs are important immune system mediators that initiate or modulate autoimmunity and tissue damage through diverse actions on cells with immune function. Type-I and type-II IFNs can have both positive and negative effects in animal models of T1D. 17 In our analysis, we explored the relationships among IFN-induced genes by IPA and showed that type-I IFN signature was preferentially expressed in PT1D. Recently, upregulation of these genes was observed in peripheral blood of patients with others diseases like SLE, 18, 19 dermatomyositis, 20 systemic sclerosis, 21 multiple sclerosis 22 and rheumatoid arthritis. 23 Our analysis revealed a striking heterogeneity in the profiles of IFNregulated genes in PT1D. Approximately, 30% of PT1D carry the type-I IFN signature (Figure 4 ) as compared with half in SLE or in rheumatoid arthritis patients, 18, 23 suggesting that other pathways may contribute more directly to the development of the organ-specific autoimmune diseases. Recently, it was shown that incubation of peripheral blood mononuclear cells of healthy blood donors with the sera of recent-onset T1D or PT1D results in the expression of IFN-induced genes, leading to the hypothesis that the IFN signature emerges years before the onset of T1D. 7 In our study, type-I IFN gene expression was not detected in blood. This suggests that the type-I IFN gene is slightly expressed in blood. Indeed, it was demonstrated that the levels of IFNa, IFNa-producing plasmacytoid dendritic cells and the expression of IFNa-inducible genes in CD4 þ T-cells were increased in the pancreatic-draining lymph nodes of NOD mice. 24 Those results observed in mice were confirmed in humans, with the detection of higher levels of IFNa mRNA and protein in the pancreas of T1D patients as compared with those in controls. 25, 26 Moreover, the delayed onset and the decreased incidence of T1D in NOD mice after blockade of IFNa receptor-1 by a The top sequence is forward primer and the bottom sequence is reverse primer. 24 In SLE patients, neutralization of IFNa was shown to prevent the maturation of dendritic cells and subsequently prevented the expansion of autoreactive Tcells. 27 Recently, clinical trials using monoclonal antibody against IFNa have shown promising results in SLE patients, 28 which could be extended to T1D; one possible area where IFNa-neutralizing or IFNa-blocking antibody may be useful for treating autoantibody-positive or highrisk-genotype pre-diabetic individuals when they first develop anti-islet autoantibodies during the long prodromal phase of pre-diabetes. However, at this stage of our study, we were not able to demonstrate that type-I IFN is an important player as in SLE or in rheumatoid arthritis. 19, 23 No statistical association was observed between the molecular stratification of PT1D (IFN high / IFN low ) and the demographic and clinical characteristics of the PT1D presented in Table 3 .
Hyperglycemia and/or exogenous insulin influence cytokine production from circulating immune cells; however, the mechanisms are still unclear. To date, the influence of hyperglycemia on type-I IFN has not yet been studied. However, Lang et al. 29 have shown a profound inhibition of IFN-g expression in osmotically shrunken cells. We can assume that type-I IFN-inducible genes could be temporarily switched-off during the acute glycemic stress period characterizing the onset of T1D. Thus, hyperglycemia by itself might explain the discontinuity of our results during the transition stage from pre-diabetes to diabetes. Another possibility might be that late b-cell failure results more from glucotoxicity and/or ER stress factors than from an immune-mediated insult.
In contrast, cluster-2 ( Figure 3a) included genes mainly associated with metabolic changes consistent with insulin deficiency and hyperglycemia, reinforcing the relevance of the results obtained using whole blood. In diabetes, cell growth is increased by high glucose concentration. 30 In our study, we identified ribosomal protein genes transcriptionally activated in the diabetic group, reflecting increase in ribosome biogenesis. This observation is corroborated by a study that has showed the effects of high glucose concentrations on Saccharomyces cerevisiae. In fact, ribosomal protein gene transcription is activated and ribosomal protein mRNA degradation is transiently inhibited. 31 These two effects increase ribosomal protein mRNA abundance, thereby accelerating ribosome biogenesis. Additional evidence for metabolic changes in our study of T1D comprises upregulation of genes of the oxidative phosphorylation pathway. This observation was confirmed in different studies showing that insulin deprivation in T1D results in increased oxygen consumption, suggesting increased rate of oxidative phosphorylation. 32, 33 The recent immunohistochemical analysis of a pancreatic gland from a patient with longstanding diabetes provided interesting clues to disease pathogenesis. 4 Interestingly, the remaining b-cells were detected in islets and within the exocrine pancreas in close vicinity of T-lymphocytes or macrophages This is consistent with the existence of a persistent autoimmune process and the inability of b-cells to regenerate from ductal cell precursors. Uncertainty about the ability of peripheral Table 3 Demographic and clinical characteristics of the subjects (40) 4 (40) 5 (50) 8 (80) 5 (56) 7 (70) 12 (60) (60) 5 (50) 2 (20) 4 (44) 3 (30) 8 (40) 10 (52.6) 8 (40) 10 ( Functional genomics in type-I diabetes F Reynier et al blood to reflect the pathological process ongoing in the pancreas has hampered many studies of humans. Currently, antibodies to b-cell antigens are the best validated markers to determine the risk of developing diabetes. 6 Peripheral T-cells that proliferate in the presence of GAD65 34 or insulin have been detected at disease onset. Moreover, T-cell clones have been produced from peripheral blood mononuclear cells of newly diagnosed patients that are home to the pancreas of NOD-SCID mice after intravenous transfer, suggesting that autoreactive T-cells circulate at the periphery. 35 Evidence shows that transcriptome analysis will offer new opportunities to identify genes that can be used for early diagnosis of diabetes. Recently, through the combined approach of microarray profiling and genetic linkage analysis, it has been shown that gene expression patterns can be inherited under a variety of conditions across a range of species.
36,37 Consequently, we expect that the association of genetic, serological and transcriptomic data could improve the monitoring of prediabetes. The present study provides new perspectives on the nature and extent of immune dysregulation, and lends further support for a central role of type-I IFN in T1D pathogenesis. Our data presented a strong rationale for the development of new therapies to block IFN pathways in human T1D. Finally, patterns of gene expression in blood cells may be useful in identifying and monitoring those individuals most likely to benefit from these therapies.
Materials and methods

Ethics statement
There are no submissions to ethical committee. This study is out of the scope of the French law related to patients participating in clinical research. Good clinical practices under ICH E6 (R1)/135/95 were implemented by the sponsor and the investigators involved in this study. Blood samples were taken during usual biological monitoring. All patients and controls provided written informed consent for the collection of samples and subsequent analysis.
Patient and control selection
Age and sex-matched recently diagnosed T1D (n ¼ 19), PT1D (n ¼ 20) and control (n ¼ 20) Caucasian children were enrolled in the study (Table 3) . Additional blood samples from T1D and PT1D children were taken during medical follow-up of their disease. T1D children were antibody-positive for GAD65 and/or IA-2, and were selected within 48-h after initiation of insulin therapy. PT1D children were siblings of T1D children. PT1D were obtained from the Rhô ne-Alpes prospective diabetes registry and were selected by the presence of antibodies to GAD65 and/or IA-2. Additional blood samples from control children were collected from preoperative test before a benign surgery (exostosis, testicular ectopia, hernia). The Controls were antibody-negative, without any familial history of T1D, autoimmune disease or infectious diseases, and had no concomitant medication. For the microarray experiments, each group was randomly divided into two subgroups (Set-1 and Set-2; Table 3 ). In a second step, we incorporated SLE patients (SLE, n ¼ 10) used as an IFN-positive control group (IFN high ). Additional blood samples of SLE, not age-and sex-matched, were collected during medical follow-up of their lupus. Selection of these patients was based on their SLE Disease Activity Index (SLEDAI), median (Q1-Q3), 13 (12-17.5).
Sample processing and microarray hybridization Peripheral blood samples were collected in PAXgene Blood RNA tubes (PreAnalytix, Hilden, Germany). This technology uses a reagent that immediately stabilizes intracellular RNA and inhibits RNA degradation and gene induction as blood is drawn directly into the tube. 15 After sample collection, the PAXgene tubes were incubated at room temperature for 2 h and then stored at À80 1C until RNA extraction. Extraction was performed according to the manufacturer's instructions. Briefly, RNA was isolated using the PAXgene Blood RNA kit (PreAnalytix). Following cell lysis, nucleic acids were pelleted and treated with a buffer containing proteinase-K. After digestion with RNase-free DNase (Qiagen, Valencia, CA, USA), the RNA was subsequently purified on PAXgene spin columns and eluted in 80 ml of elution buffer. RNA integrity was assessed using RNA 6000 nanochips and an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany), according to the manufacturer's instructions. The RNA integrity number (RIN) software was used to estimate the integrity of total RNA samples from the entire electrophoretic trace of the RNA sample. 38 cRNA was synthesized using 3 mg of total RNA following the Affymetrix (Santa Clara, CA, USA) protocol. cRNA was transcribed in vitro by incorporating a biotinylated pseudouridine molecule using GeneChip Expression 3 0 -Amplification Reagents for IVT Labeling, overv16 h at 37 1C (Affymetrix). Hybridization was performed using GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix) containing 54 675 probe sets corresponding to 38 500 identified genes. After washing, the chips were stained with streptavidin-phycoerythrin according to the Affymetrix EukGE-WS2v5 protocol using a Fluidic FS450 station. The microarrays were read with the GeneChip Scanner 3000 (Affymetrix). The Affymetrix GeneChip Operating Software version 1.2 (GCOS) was used to manage the Affymetrix GeneChip array data and to automate the control of the GeneChip fluidics stations and scanners.
Data analysis
Expression data were generated by the Robust Multiarray Average (RMA) method 39 implemented in the qAffy package of the Bioconductor microarray analysis environment (http://www.bioconductor.org). The RMA method consists of three steps: background adjustment, quantile normalization 40 and probe set summary of the log-normalized data by applying a median polishing procedure.
Initially, the normalized data were analyzed using an approach based on MDS techniques and visualized using the Spotfire Decision Site 8.2.1 for Functional Genomics software (Spotfire, Gothenburg, Sweden). To gain insight into the molecular pattern among the three classes, MDS made it possible to obtain a projection of high-dimensional data into a lower dimensional space in order to examine relationships between sample profiles. Controls, PT1D and T1D were placed in a three-dimensional Euclidean space, according to their expression patterns, Before subsequent statistical comparisons between groups, we applied filter based on variability. The interquartile range was used as the filtering criterion. Thus, we considered genes with an inter-quartile range below 0.5 as invariant genes. The genes differentially expressed were identified by comparing the three groups (PT1D, T1D and controls) using the SAM method (FDR ¼ 0.05; number of permutations: n ¼ 1000). 41 This approach was applied to Set-1, Set-2 and Set-1 þ 2 separately, and only genes common between the three analyses were selected. In parallel, to assess the reliability of the identified genes, post hoc analyses were conducted to establish the statistical power of the study. The Sizepower package (version 1.8) from Bioconductor Environment was used to address power analysis for each set. 42 To go further into the description of genes identified as differentially expressed, three pairwise comparisons (controls versus T1D, controls versus PT1D, T1D versus PT1D) were also performed using the same approach (FDR ¼ 0.1; number of permutations: n ¼ 1000).
To visualize the expression profiles of genes differentially expressed among the three groups, and to investigate their relationships, a k-means clustering was performed with Spotfire Decision Site 8.2.1. This method used the median expression levels adjusted to the Z-score-normalized data set. Cluster initialization was performed using the data centroid-based search parameter and the level of similarity was calculated based on Euclidean distance. The k-means clustering was applied using a k-value (that is, number of clusters) of 2, 3, 4, 5 and 6. To assess the reliability of each cluster, the Clusterv package based on R 2.4 was applied to the Z-score-normalized data set to redo the k-means clustering. 43 Estimation of stability was achieved through random projections of the original high-dimensional data to lower dimensional subspaces. These random projections were repeated many times and each time a new clustering was performed. The multiple clusterings obtained were then compared with the initial clustering we wanted to evaluate. Intuitively, a cluster was considered reliable if it could be maintained across multiple clusterings performed in the lower dimensional subspaces.
Each gene set identified with the k-means clustering approach was classified using an ontological method to structure biological knowledge. For this purpose, the DAVID Bioinformatics Resources (http://david.abcc. ncifcrf.gov) was used to enhance biological interpretation. 44, 45 This tool incorporates information from different public resources and provides an easy way to make biological sense out of large sets of genes. 46 In order to identify GO categories, the EASE score (modified Fisher exact P-value) was used for gene-enrichment analysis (significance level at 0.05).
IFN molecular pathway analysis
For IFN signature analysis, we used the IFN-response genes (selected in the previous analysis: Set-1-Set-2-Set-1 þ 2). Before selection of IFN-response genes, expression data were generated again by RMA method, including the fourth group composed of the SLE patients. For each individual we calculated the average expression of the IFN genes identified in the ontological analysis (Figure 3a; cluster-1; immunological processes ; IFI27, OASL, SERPING1, ISG15, IFIT3,  GBP1, IFIT2, IFIT1, OAS3, STAT1, RSAD2, IFI44) . We defined individuals showing altered IFN-response by calculating the 90 percentile limits of the controls (normal values, defined by a non-parametric ranking method based on the log2 mean expression of the 12 IFN genes). Thus, individuals below the threshold were classified as IFN high and vice versa, individuals presenting expression measures below the threshold were assigned as IFN low . From the 12 genes, which comprised the IFN signature, networks of the IFN genes were constructed using IPA (www.ingenuity.com). Out of the 12 IFN genes, there are those that were found in the IPA knowledge database, and are labeled 'focus' genes. On the basis of the focus genes, IPA generated a set of molecular networks, with a cutoff of 35 genes for each network, based on interactions between uploaded genes and all other genes/proteins stored in the knowledge base. Each network is assigned a score according to the number of focus genes in our data set. These scores are derived from negative logarithm of the P-value, indicative of the likelihood that that focus genes are found together in a network due to random chance. Scores of 4 or higher have 99.9% confidence level of significance as defined in detail elsewhere. 47 mRNA expression analysis by quantitative real-time RT-PCR For a subset of patients (n ¼ 28), 0.5 mg of total RNA was reverse transcribed into cDNA using the ThermoScript RT-PCR system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Quantitative PCR analysis was performed using the LighCycler 2.0 (Roche Diagnostics, Mannheim, Germany) using the LightCycler À FastStart DNA Master PLUS SYBR Green I kit according to the manufacturer's instructions (Roche Diagnostics). Thermocycling was performed in a final volume of 20 ml containing 3 mM MgCl 2 and 0.5 mM of each of the required primers. PCR was performed with an initial denaturation step of 10 min at 95 1C, followed by 40 cycles of touch-down PCR protocol (10 s at 95 1C, 10 s annealing at 68-58 1C and 16 s extension at 72 1C). mRNA expression of the housekeeping gene peptidylpropyl isomerase-B (PPIB) encoding for cyclophilin-B was investigated using cDNA standards and ready-touse primer mixes obtained from Seach-LC (Heidelberg, Germany) as previously described. 48 The cDNA standard for selected genes was prepared from purified PCR amplicons. Primer designs and reaction performance parameters are provided in Table 1 . LightCycler 2.0 was used to determine the crossing point for individual samples. Serial dilutions of the cDNA standard were prepared in quadruplicate to generate standard curves. Relative standard curves describing the PCR efficiency of selected genes and the housekeeping gene were created and used to perform efficiencycorrected quantification with the LightCycler Software version 4.05. Gene expression values were expressed as a concentration ratio of target gene mRNA/PPIB. Correlation between the concentration ratio and Affymetrix-normalized data was studied using Spearman correlation test.
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